My wife was diagnosed with breast cancer. The oncologist had almost no data to personalize her treatment. In 2015. I thought: this is insane. We have more data on what movies people watch than on how to treat their cancer.
We've built the world's largest library of clinical and molecular data in oncology. Genomic sequencing, pathology, imaging, clinical records — all connected. That data set doesn't exist anywhere else.
I co-founded Groupon. Built it to a $30 billion IPO. It was the fastest-growing company in history at the time. Tempus is harder. But it matters more. Coupons versus cancer. Easy choice.
We went public in 2024 at a $6 billion valuation. For a precision medicine company. Not a drug company — a data company that helps doctors choose the right drug. That's a new category.
Doctors are making life-and-death decisions with incomplete data every single day. Tempus gives them the full picture — genomics, imaging, clinical history — so the decision is informed, not intuitive.
We partner with every major cancer center in the US. Over 50% of oncologists in America use Tempus. When you have that kind of adoption, the data flywheel becomes unstoppable — more data, better insights, more adoption.